Literature DB >> 27548593

Systemic Lupus Erythematosus: Primary Care Approach to Diagnosis and Management.

Nguyet-Cam Vu Lam1, Maria V Ghetu1, Marzena L Bieniek1.   

Abstract

Systemic lupus erythematosus is an autoimmune disease that affects many systems, including the skin, musculoskeletal, renal, neuropsychiatric, hematologic, cardiovascular, pulmonary, and reproductive systems. Family physicians should be familiar with the manifestations of lupus to aid in early diagnosis, monitoring patients with mild disease, recognizing warning signs that require referral to a rheumatologist, and helping to monitor disease activity and treatment in patients with moderate to severe disease. The American College of Rheumatology has 11 classification criteria for lupus. If a patient meets at least four criteria, lupus can be diagnosed with 95% specificity and 85% sensitivity. All patients with lupus should receive education, counseling, and support. Hydroxychloroquine is the cornerstone of treatment because it reduces disease flares and other constitutional symptoms. Low-dose glucocorticoids can be used to treat most manifestations of lupus. The use of immunosuppressive and cytotoxic agents depends on the body systems affected. Patients with mild disease that does not involve major organ systems can be monitored by their family physician. Patients with increased disease activity, complications, or adverse effects from treatment should be referred to a rheumatologist. To optimize treatment, it is important that a rheumatologist coordinate closely with the patient's family physician to improve chronic care as well as preventive health services.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27548593

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.

Authors:  S Kabadi; J Yeaw; A K Bacani; E Tafesse; K Bos; S Karkare; M DeKoven; E R Vina
Journal:  Lupus       Date:  2018-08-01       Impact factor: 2.911

2.  Implementation and dissemination of an African American popular opinion model to improve lupus awareness: an academic-community partnership.

Authors:  C R Phillip; K Mancera-Cuevas; C Leatherwood; J S Chmiel; D L Erickson; E Freeman; G Granville; M Dollear; K Walker; R McNeil; C Correia; P Canessa; R Ramsey-Goldman; C H Feldman
Journal:  Lupus       Date:  2019-10-08       Impact factor: 2.911

Review 3.  Autoimmune vertigo: an update on vestibular disorders associated with autoimmune mechanisms.

Authors:  Francesca Yoshie Russo; Massimo Ralli; Daniele De Seta; Patrizia Mancini; Alessandro Lambiase; Marco Artico; Marco de Vincentiis; Antonio Greco
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

4.  Yoga for systemic lupus erythematosus (SLE): Clinician experiences and qualitative perspectives from students and yoga instructors living with SLE.

Authors:  Kimberly R Middleton; Steffany Haaz Moonaz; Sarfaraz A Hasni; Miriam Magaña López; Gladys Tataw-Ayuketah; Nicole Farmer; Gwenyth R Wallen
Journal:  Complement Ther Med       Date:  2018-09-08       Impact factor: 2.446

Review 5.  An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus.

Authors:  Amit Thakral; Marisa S Klein-Gitelman
Journal:  Rheumatol Ther       Date:  2016-09-30

6.  Ability and willingness to utilize telemedicine among rheumatology patients-a cross-sectional survey.

Authors:  Steve S Kong; Lilian A Otalora Rojas; Amnie Ashour; Mathew Robinson; Tyler Hosterman; Neha Bhanusali
Journal:  Clin Rheumatol       Date:  2021-07-04       Impact factor: 2.980

Review 7.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

Review 8.  Cell-bound complement activation products in SLE.

Authors:  Rosalind Ramsey-Goldman; Jian Li; Thierry Dervieux; Roberta Vezza Alexander
Journal:  Lupus Sci Med       Date:  2017-08-21

9.  Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.

Authors:  Jeffrey M Riggs; Richard N Hanna; Bhargavi Rajan; Kamelia Zerrouki; Jodi L Karnell; Divya Sagar; Inna Vainshtein; Erika Farmer; Kimberly Rosenthal; Chris Morehouse; Melissa de Los Reyes; Kevin Schifferli; Meina Liang; Miguel A Sanjuan; Gary P Sims; Roland Kolbeck
Journal:  Lupus Sci Med       Date:  2018-04-05

10.  Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl.

Authors:  Tuğba Şişmanlar Eyüboğlu; Ayşe Tana Aslan; Yeşim Özdemir; Deniz Gezgin Yıldırım; Necla Buyan; Öznur Boyunağa
Journal:  Auto Immun Highlights       Date:  2018-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.